JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic Value of an Immune Long Non-Coding RNA Signature in Liver Hepatocellular Carcinoma

  • 0Department of Gastroenterology, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University, P.R. China.
Journal of Microbiology and Biotechnology +

|

March 18, 2024

|

March 18, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study identifies a six-long non-coding RNA (lncRNA) signature for predicting hepatocellular carcinoma (LIHC) prognosis. This immune-related lncRNA profile offers potential for accurate diagnosis and treatment strategies in LIHC patients.

Area Of Science

  • Oncology
  • Immunology
  • Molecular Biology

Background

  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in hepatocellular carcinoma (LIHC) immunity.
  • Certain lncRNAs show promise for LIHC diagnosis and treatment.

Purpose Of The Study

  • To develop an immune lncRNA profile for assessing the diagnostic and prognostic significance of immune-associated lncRNAs in LIHC.
  • To identify a robust signature for predicting LIHC patient outcomes.

Main Methods

  • Screened TCGA LIHC gene expression data for immune-related genes.
  • Constructed an immune lncRNA signature using correlation and Cox regression analyses.
  • Evaluated prognostic capability via Kaplan-Meier, ROC, clinical, GSEA, and PCA analyses.

Main Results

  • Identified a six-lncRNA signature associated with immune genes.
  • Classified LIHC samples into distinct risk groups with significant survival differences.
  • Demonstrated the signature's independent prognostic value and predictive performance.

Conclusions

  • The developed six-lncRNA signature serves as a potential independent predictor for LIHC prognosis.
  • This signature may aid in improving diagnostic accuracy and guiding treatment strategies for LIHC.

Keywords: